Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon Links Up with US Health Tech for R&D on Blood Collection and Stabilization Device
October 28, 2020
- Pharma’s Half-Year Earnings Season in Full Swing from This Week
October 27, 2020
- Ono Says Honjo’s 22.6 billion Yen Claim Groundless, No Agreement Reached on 40% Opdivo Fee Proposal
October 27, 2020
- Medicago Inks COVID-19 Vaccine Deal with Canadian Govt
October 27, 2020
- NC-6004-Keytruda Combo Racks Up Positive US PIIa Results for Head and Neck Cancer: NanoCarrier
October 27, 2020
- CureApp Launches Prescription Platform for Therapeutic Apps
October 26, 2020
- Mitsubishi Chemical Taps Belgium-Born Gilson as Its First Foreign CEO
October 26, 2020
- Exploratory Trial of Neuro-Protective/Regenerative Sheets to Be Launched for CTS: Osaka Univ., NIMS, Nippon Zoki
October 26, 2020
- Nichi-Iko’s Remicade Biosimilar Adds Ankylosing Spondylitis Use
October 26, 2020
- Sanwa Kagaku’s SHPT Drug Meets Primary Goal in Japan PIII
October 26, 2020
- Cyberattacks Leak Data from Shionogi’s Taiwan Subsidiary
October 26, 2020
- Novartis Looks to Solidify Presence in Multiple Sclerosis Arena with Mayzent, then Ofatumumab
October 23, 2020
- Chugai Enjoys Higher Earnings in January-September on Hemlibra
October 23, 2020
- Fujifilm Taps Carelink as Chinese Partner for Avigan
October 23, 2020
- Daiichi Sankyo Kicks Off PI Study for I/O Therapy DS-1055
October 23, 2020
- AstraZeneca’s Japan COVID-19 Vaccine Trial Ongoing after Death Reported in Brazil
October 23, 2020
- Kyowa Kirin Delivers Positive PIIb Data for Parkinson’s Med KW-6356
October 22, 2020
- Aducanumab Filed in Europe: Biogen/Eisai
October 22, 2020
- Chugai Licenses Antibody Engineering Tech to Novo
October 22, 2020
- GSK Sets Up Oncology Biz Unit in Japan; Multiple Late-Stage Assets in Pipeline
October 22, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…